Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPPL1 | O15357 | 3/20 | 0.39 |
| ▸ | INPP5A | Q14642 | 3/20 | 0.39 |
| ▸ | INPP5B | P32019 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2B | P41595 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 4/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952832 | 0.80 | INPPL1 (0.39) | INPPL1INPP5AINPP5BHTR2CHTR2B | |
| SCHEMBL5951744 | 0.76 | INPPL1 (0.45) | INPPL1INPP5AINPP5BHTR2CHTR2B | |
| SCHEMBL5952508 | 0.68 | INPPL1 (0.37) | INPPL1INPP5AINPP5BHSD11B1SRC | |
| SCHEMBL5952374 | 0.64 | INPPL1 (0.44) | INPPL1INPP5AINPP5BHTR2CHTR2B | |
| SCHEMBL11254931 | 0.62 | INPPL1 (0.45) | INPPL1INPP5AINPP5BSRCKDM4E | |
| SCHEMBL31555373 | 0.62 | INPPL1 (0.57) | INPPL1INPP5AINPP5BHTR2CHTR2B | |
| SCHEMBL1192358 | 0.61 | INPPL1 (0.46) | INPPL1INPP5AINPP5BHTR2CHTR2B | |
| SCHEMBL29647909 | 0.60 | INPPL1 (0.53) | INPPL1INPP5AINPP5BHTR2CHTR2B | |
| SCHEMBL1101447 | 0.60 | INPPL1 (0.53) | INPPL1INPP5AINPP5BHTR2CHTR2B | |
| SCHEMBL14632746 | 0.60 | INPPL1 (0.53) | INPPL1INPP5AINPP5BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038070-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2006-05-02 | — | — | US | disclosed |
| US-6963017-B2 | Preparation of preparing substituted indanones | BASELL POLYOLEFINE GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-0968158-B1 | METHOD OF PREPARING SUBSTITUTED INDANONES, THE SUBSTITUTED INDANONES AND METALLOCENES PREPARED THEREFROM | BASELL POLYOLEFINE GMBH (DE) | 2005-08-10 | — | — | EP | disclosed |
| US-20050033076-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2005-02-10 | — | — | US | disclosed |
| US-20030009046-A1 | Preparation of preparing substituted indanones | EQUISTAR CHEMICALS, LP | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033076-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP2J2, IDH3A | INPPL1 2445/4885INPP5A 1278/4885INPP5B 1007/4885 |
| US-20030009046-A1 | Preparation of preparing substituted indanones | CYP1A2, CYP1B1, CYP1A1 | INPPL1 2482/4885INPP5A 1248/4885INPP5B 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.